Treatment of Fabry disease: outcome of a comparative trial with agalsidase alfa or beta at a dose of 0.2 mg/kg
about
Early diagnosis of peripheral nervous system involvement in Fabry disease and treatment of neuropathic pain: the report of an expert panelEnzyme replacement therapy for Anderson-Fabry diseaseEnzyme replacement therapy for Anderson-Fabry diseasePain management strategies for neuropathic pain in Fabry disease--a systematic reviewAgalsidase alfa: a review of its use in the management of Fabry diseaseReceptor-mediated endocytosis of α-galactosidase A in human podocytes in Fabry diseaseSubstrate reduction augments the efficacy of enzyme therapy in a mouse model of Fabry diseaseTemporal intradiploic dilative vasculopathy: an additional pathogenic factor for the hearing loss in fabry disease?Stroke and Fabry disease.Small fibers in Fabry disease: baseline and follow-up data under enzyme replacement therapy.Long-term effect of antibodies against infused alpha-galactosidase A in Fabry disease on plasma and urinary (lyso)Gb3 reduction and treatment outcomeEnzyme replacement therapy for Fabry disease: some answers but more questionsImpaired small fiber conduction in patients with Fabry disease: a neurophysiological case-control studyUpdate on role of agalsidase alfa in management of Fabry disease.Limitations of drug registries to evaluate orphan medicinal products for the treatment of lysosomal storage disorders.Biomarkers in the diagnosis of lysosomal storage disorders: proteins, lipids, and inhibodies.Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document.Consequences of a global enzyme shortage of agalsidase beta in adult Dutch Fabry patients.Rapid Immunochromatographic Detection of Serum Anti-α-Galactosidase A Antibodies in Fabry Patients after Enzyme Replacement Therapy.Efficient uptake of recombinant α-galactosidase A produced with a gene-manipulated yeast by Fabry mice kidneysEfficacy of Enzyme and Substrate Reduction Therapy with a Novel Antagonist of Glucosylceramide Synthase for Fabry DiseaseSkin Globotriaosylceramide 3 Load Is Increased in Men with Advanced Fabry Disease.Neutralizing antibodies to therapeutic enzymes: considerations for testing, prevention and treatmentEffect of reduced agalsidase Beta dosage in fabry patients: the Australian experienceElevated globotriaosylsphingosine is a hallmark of Fabry disease.Agalsidase benefits renal histology in young patients with Fabry disease.Recommendations on reintroduction of agalsidase Beta for patients with fabry disease in europe, following a period of shortage.Enzyme replacement therapy for Fabry disease: A systematic review and meta-analysis.Cost-effectiveness of enzyme replacement therapy for Fabry diseaseVariations in the GLA gene correlate with globotriaosylceramide and globotriaosylsphingosine analog levels in urine and plasma.Long term enzyme replacement therapy for Fabry disease: effectiveness on kidney, heart and brain.Early therapeutic intervention in females with Fabry disease?Guidelines for the primary prevention of stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association.Agalsidase alfa (Replagal) in the treatment of Anderson-Fabry diseaseReduction of Plasma Globotriaosylsphingosine Levels After Switching from Agalsidase Alfa to Agalsidase Beta as Enzyme Replacement Therapy for Fabry DiseaseHuman cell lines for biopharmaceutical manufacturing: history, status, and future perspectives.Increased arterial diameters in the posterior cerebral circulation in men with Fabry disease.Glycosphingolipid storage in Fabry mice extends beyond globotriaosylceramide and is affected by ABCB1 depletion.Emerging drugs for lysosomal storage diseases.Effects of enzyme replacement therapy in Fabry disease--a comprehensive review of the medical literature.
P2860
Q21261394-635F4889-B548-46CF-A1DD-E8421C84CA34Q24200877-5EF656DB-D6B9-4803-AB73-FEED2E368BDAQ26471010-AA009CA5-57BC-4E87-829C-E654253F312EQ26766561-6DF537C0-7633-4973-B729-F33AE98D386FQ28274194-70337B1F-F58B-450C-9344-D992EFBAED65Q28477142-7DC06E1A-0D62-4FD6-B507-3BB48245685DQ28748170-DDD77A8F-FAD5-4238-89D2-35BA5A1CF813Q30458149-EE0AF5A4-9180-48D9-B18A-8B79FCA6085EQ34061632-AFE3E63F-2478-4485-BAB7-4CC952531EBBQ34103791-75A42DD6-6FA3-420F-899A-CB2A1029F1E9Q34456578-EBB06526-5C08-43B3-A5A5-77A3B3B8E0D3Q34703815-791B4C13-F91B-4DA6-84A6-7BFAF0A781BAQ34739186-880275E1-78BE-4BEF-B675-68BD8EA459B0Q34883178-75034177-88BB-4470-8348-984831364B22Q35009083-A347101A-ACA9-4E58-A856-4FDD167734EBQ35028532-95617D97-7FED-475C-86C1-3E2603D1EB0FQ35247511-1C8C7057-C182-4A6B-AA3A-6BD5B6D10F3FQ35560027-38F76DF6-F316-4ECA-A3F6-C8AA13D0A28CQ35665871-34718406-D4B4-401C-9A98-3BB3AD3FF598Q35719001-EC704025-4F0F-4929-AA99-E9E82B6FA44AQ36025702-70374DAA-50BF-4E8E-ADB5-EC93D89ADEDDQ36193984-1EA29E46-1782-4C75-B8C1-10F69151D1E1Q36338254-71236C76-246F-4F89-BFC1-5AEBE701C4D6Q36433306-D0744F46-70F9-4E37-93F9-A0002A07F852Q36498349-487312E3-85A3-4A78-B60D-140FD6977419Q36509288-28F3BF46-8F4F-4607-AA02-AD983BE7C1BEQ36590963-6245039E-F90E-4063-B755-072159098951Q36607211-9C811088-3091-4EDB-8C5C-E683CC1A3536Q36688268-BEA4FCFA-24E7-4F34-8976-D7A37BF94976Q36691965-7A0404D6-939A-430C-8DE1-8104FF3E9500Q36767452-F57DF649-43C7-47C0-B08A-66D0D4DC06EAQ37109597-FA4A8971-FDC5-4B31-8D42-63384FE32465Q37251490-339228E7-CA4F-4EC2-A0BA-80D8A2F852B9Q37290507-2A7FCAC5-A38F-41A2-A249-A622CB8C6E18Q37329223-2BD58F44-DBB4-4E1B-9D2E-F305ED07A140Q37494846-73E6E743-8B24-4B15-8BF7-0A724E6BA580Q37521065-04D4BC06-02D5-4E3F-B261-79DA3351C0D6Q37591813-18C5673E-B0B0-449C-88C0-9249DF9E8C3FQ37765901-CDA76845-2458-4738-A050-DB2683D4B1EDQ37801828-047D9C86-451B-4EC0-AD73-9C2FB9696915
P2860
Treatment of Fabry disease: outcome of a comparative trial with agalsidase alfa or beta at a dose of 0.2 mg/kg
description
2007 nî lūn-bûn
@nan
2007 թուականին հրատարակուած գիտական յօդուած
@hyw
2007 թվականին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Treatment of Fabry disease: ou ...... or beta at a dose of 0.2 mg/kg
@ast
Treatment of Fabry disease: ou ...... or beta at a dose of 0.2 mg/kg
@en
Treatment of Fabry disease: ou ...... or beta at a dose of 0.2 mg/kg
@en-gb
Treatment of Fabry disease: ou ...... or beta at a dose of 0.2 mg/kg
@nl
type
label
Treatment of Fabry disease: ou ...... or beta at a dose of 0.2 mg/kg
@ast
Treatment of Fabry disease: ou ...... or beta at a dose of 0.2 mg/kg
@en
Treatment of Fabry disease: ou ...... or beta at a dose of 0.2 mg/kg
@en-gb
Treatment of Fabry disease: ou ...... or beta at a dose of 0.2 mg/kg
@nl
prefLabel
Treatment of Fabry disease: ou ...... or beta at a dose of 0.2 mg/kg
@ast
Treatment of Fabry disease: ou ...... or beta at a dose of 0.2 mg/kg
@en
Treatment of Fabry disease: ou ...... or beta at a dose of 0.2 mg/kg
@en-gb
Treatment of Fabry disease: ou ...... or beta at a dose of 0.2 mg/kg
@nl
P2093
P2860
P1433
P1476
Treatment of Fabry disease: ou ...... or beta at a dose of 0.2 mg/kg
@en
P2093
Anouk C Vedder
Asle Hirth
Berto J Bouma
Carla E M Hollak
Els E Ormel
Gabor E Linthorst
Gunnar Houge
Johannes M F G Aerts
Johannna E M Groener
P2860
P356
10.1371/JOURNAL.PONE.0000598
P407
P577
2007-01-01T00:00:00Z